Enhancement of nasal salmon calcitonin absorption by lauroylcarnitine chloride in rats

Pharmaceutical Research

Volumn 13, Issue 5, 1996, Pages 739-743

  Kagatani, Seiya ^a   Shinoda, Tatsuki ^a   Fukui, Muneo ^a   Ohmura, Tadayoshi ^a   Hasumi, Shunji ^a   Sonobe, Takashi ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Lauroylcarnitine; Micelle formation; Nasal absorption enhancer; Salmon calcitonin

Indexed keywords

ACYLCARNITINE; CARNITINE; CARNITINE DERIVATIVE; LAUROYLCARNITINE; PALMITOYLCARNITINE; SALCATONIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG FORMULATION; INTRANASAL DRUG ADMINISTRATION; MALE; NONHUMAN; NOSE MUCOSA; OSMOLARITY; PH; PHARMACOKINETICS; PRIORITY JOURNAL; RAT;

ADMINISTRATION, INTRANASAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CALCITONIN; CARNITINE; HYDROGEN-ION CONCENTRATION; LAURATES; MALE; OSMOLAR CONCENTRATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0029992929     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016051600828     Document Type: Article

References (15)

1. W. A. Lee, R. D. Ennis, J. P. Longenecker and P. Bengtsson. The bioavailability of intranasal salmon calcitonin in healthy volunteers with and without a permeation enhancer. Pharm. Res. 11:747-750 (1994).
2. A. E. Pontiroli, M. Alberetto, A. Calderara, E. Pajetta and G. Pozza. Nasal administration of glucagon and human calcitonin to healthy subjects: a comparison of powders and spray solutions and of different enhancing agents. Eur. J. Clin. Pharmacol. 37:427-430 (1989).
3. S. Kagatani, S. Hasumi, T. Watanabe, T. Usui and T. Sonobe. The nasal absorption of salmon calcitonin. Yakuzaigaku 51:65-72 (1991).
4. L. H. Opie. Role of carnitine in fatty acid metabolism of normal and ischemic myocardium. Am. Heart J. 97:375-388 (1979).
5. J. A. Fix, K. Engle, P. A. Porter, P. S. Leppert, S. J. Selk, C. R. Gardner and J. Alexander. Acylcarnitines: drug absorption- enhancing agents in the gastrointestinal tract. Am. J. Physiol. 251:G332-340 (1986).
6. J. L. Richardson, P. S. Minhas, N. W. Thomas and L. Illum. Vaginal administration of gentamicin to rats. Pharmaceutical and morphological studies using absorption enhancers. Int. J. Pharm. 56:29-35 (1989).
7. E. L. Lecluyse, S. C. Sutton and J. A. Fix. In vitro effects of long- chain acylcarnitines on the permeability, transepithelial electrical resistance morphology of rat colonic mucosa. J. Pharmacol. Exp. Ther. 265:955-962 (1993).
8. J. H. Hochman, J. A. Fix and E. L. Lecluyse. In vitro and in vivo analysis of the mechanism of absorption enhancement by palmitoylcarnitine. J. Pharmacol. Exp. Ther. 269:813-822 (1994).
9. S. Hirai, T. Yashiki and H. Mima. Effect of surfactants on the nasal absorption of insulin in rats. Int. J. Pharm. 9:165-172 (1981).
10. J. P. Longenecker, A. C. Moses, J. S. Flier, R. D. Silver, M. C. Carey and E. J. Dubovi. Effects of sodium taurodihydrofusidate on nasal absorption of insulin in sheep. J. Pharm. Sci. 76:351-355 (1987).
11. S. H. Yalkowsky and G. Zografi. Potentiometric titration of monomeric and micellar acylcarnitines. J. Pharm. Sci. 59:798-802 (1970).
12. G. S. Gordon, A. C. Moses, R. D. Silver, J. S. Flier and M. C. Carey. Nasal absorption of insulin: enhancement by Hydrophobic bile salts. Proc. Natl. Acad. Sci. 82:7419-7423 (1985).
13. K. Morimoto, M. Miyazaki and M. Kakemi. Effects of proteolytic enzyme inhibitors on nasal absorption of salmon calcitonin in rats. Int. J. Pharm. 113:1-8 (1995).
14. E. L. LeCluyse, L. E. Appel and S. C. Sutton. Relationship between drug absorption enhancing activity and membrane perturbing effects of acylcamitines. Pharm. Res. 8:84-87 (1991).
15. G. Kumaravel, C. L. Ashendel and R. D. Candour. Hemicholinium and related lipids: inhibitors of protein kinase C. J. Med. Chem. 36:177-178 (1993).